Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec 27:11:10821-10826.
doi: 10.2147/CMAR.S219984. eCollection 2019.

Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small-Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)

Alain Vergnenègre  1 , Victor Basse  2 , Gwenaelle Le Garff  3 , Olivier Bylicki  4 , Catherine Dubos-Arvis  5 , Bénédicte Comet  6 , Marie Marcq  7 , Jacques Le Treut  8 , Jean-Bernard Auliac  9 , Anne Madroszyk  10 , Gislaine Fraboulet  11 , Jacky Crequit  12 , Pascal Thomas  13 , Nicolas Paleiron  14 , Isabelle Monnet  15 ; French Lung Cancer Group
Affiliations

Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small-Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)

Alain Vergnenègre et al. Cancer Manag Res. .

Abstract

Background: Antiangiogenic agents have improved the prognosis of non-squamous non-small-cell lung cancers (NSCLCs), even though all the patients are not eligible to receive them because of counterindications linked to the tumor's characteristics or comorbidities. Much less information is available about the eligibility of patients with squamous non-small-cell lung cancers (SQ-NSCLCs) to receive antivascular endothelial growth-factor (VEGF) treatments, even though such molecules are being developed for this histology. This study was undertaken to determine the percentage of advanced SQ-NSCLC patients who would be eligible to receive an antiVEGF agent as second-line systemic therapy.

Methods: This observational, multicenter, prospective study evaluated advanced SQ-NSCLC patients' criteria for ineligibility to receive an antiVEGF during a multidisciplinary meeting to choose their standard second-line systemic therapy.

Results: Among the 317 patients included, 53.6% had at least one ineligibility criterion, and ~20% had at least two, with disease extension to large vessels (39.8%), tumor cavitation (20.5%), cardiovascular disease (11%) and/or hemoptysis (7.2%) being the most frequent. Patients with an ECOG performance score of 1/2 had more cardiovascular contraindications that those with scores of 0.

Conclusion: Almost half of the SQ-NSCLC patients included in this study would have been eligible to receive an antiVEGF agent. The development of these molecules for these indications should be encouraged.

Keywords: antiangiogenic treatments; lung cancer; squamous non-small cell.

PubMed Disclaimer

Conflict of interest statement

A. Vergnenègre has received honoraria for consultancies and fees for medical conferences from MSD, Hoffman–La Roche, BMS, Pierre-Fabre Oncology, AstraZeneca, and Boehringer Ingelheim. Dr Olivier Bylicki reports personal fees from MSD, personal fees from ROCHE, personal fees from ASTRA-ZENECA, during the conduct of the study. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Flow chart of the study. Patients could have more than 1 ineligibility criterion.
See this image and copyright information in PMC

References

    1. American Cancer Society. Cancer Facts & Figures. Vol. 1; 2019:219
    1. Ferrara R, Mezquita L, Besse B. Progress in the management of advanced thoracic malignancies in 2017. J Thorac Oncol. 2018;13(3):301–322. doi:10.1016/j.jtho.2018.01.002 - DOI - PubMed
    1. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998–2006. doi:10.1001/jama.2014.3741 - DOI - PMC - PubMed
    1. Sandler A, Yi J, Dahlberg S, et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol. 2010;5(9):1416–1423. doi:10.1097/JTO.0b013e3181da36f4 - DOI - PubMed
    1. Zhang H, Huang Z, Zou X, et al. Bevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trials. Oncotarget. 2016;7(50):82473–82481. doi:10.18632/oncotarget.12666 - DOI - PMC - PubMed